Skip to main content

Incyte, Epoch Biosciences Enter Licensing and Development Deal

SAN FRANCISCO, Oct. 10 – Incyte Genomics has enter a licensing and development alliance with molecular tools manufacturer Epoch Biosciences, the companies announced Wednesday.

The terms include Epoch’s licensing Palo Alto-based Incyte’s LifeSeq Gold and ZooSeq databases for development of oligonucleotide probes and Incyte naming Epoch the “preferred provider” of custom oligonucleotide probes in addition to receiving Epoch Eclipse Probe Systems for use in internal development.

Financial details of the agreement were not disclosed.

“Epoch is recognized for its leading technologies related to the development of enhanced genetic analysis tools,” Roy A. Whitfield, CEO of Incyte, said in a statement. “This alliance with Epoch leverages their probe design and manufacturing capabilities and provides our users of LifeSeq Gold with a source of reliable probes to enhance their genetic analysis and research efforts.”

Epoch Biosciences is based in Bothell, Wash.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.